KA | Kineta, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.7540 - 0.8890
52 Week Range	0.3340 - 5.39
Beta	0.89
Implied Volatility	N/A
IV Rank	44.30%
Day's Volume	149,480
Average Volume	628,916
Shares Outstanding	12,261,400
Market Cap	9,953,805
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-02-11

Valuation
Profitability
Growth
Health
P/E Ratio	-0.49
Forward P/E Ratio	N/A
EPS	-1.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	11
Country	USA
Website	KA

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.

KA's peers: BYSI, DYAI, INKT, KTRA, IMNN, LSTA, RZLT, CYT, XOMAO, PTIX, TPST, CADL, FBRX, ALVR, DMAC, SILO, PTIXW, LUMO, ANEB, MOLN, MLYS, ANTX, PHVS, PEPG

*Chart delayed

Analyzing fundamentals for KA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see KA Fundamentals page.

Watching at KA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on KA Technicals page.